Skip to main content
Top
Published in: Clinical Rheumatology 7/2017

01-07-2017 | Brief Report

Validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 in English- and Chinese-speaking patients in a multi-ethnic Singapore systemic sclerosis cohort

Authors: Andrea Hsiu Ling Low, Xiaohui Xin, Weng Giap Law, Gim Gee Teng, Amelia Santosa, Anita Lim, Grace Chan, Swee Cheng Ng, Julian Thumboo

Published in: Clinical Rheumatology | Issue 7/2017

Login to get access

Abstract

The aim of this study was to (1) translate the Gastrointestinal Tract Instrument (GIT) 2.0 from English to Chinese and (2) validate both versions in a multi-ethnic systemic sclerosis cohort in Singapore (SCORE). The English GIT2.0 was translated to Chinese using a standard forward-backward translation approach. Psychometric evaluation of the GIT2.0 included internal consistency reliability (using Cronbach’s alpha), test-retest reliability (using intra-class correlation coefficient (ICC)), scale level factor analysis, and construct validity (using Spearman correlation) against the modified Scleroderma Health Assessment Questionnaire (S-HAQ) and the SF-36 v2. Most of the patients were females (88.6%) and Chinese (78.2%), with mean (SD) age of 51.0 (13.0) years and median disease duration of 4.5 years. We administered English (n = 146) and Chinese (n = 74) GIT2.0. The mean (SD) total GIT score was 0.29 (0.37). There was good internal consistency (Cronbach’s alpha >0.70 for all subscales) and good test-retest reliability for the scale and all subscales (ICC 0.71–0.92) except for “diarrhoea” (ICC = 0.54). Our hypothesised a priori construct validity was supported by moderate correlations between the total GIT score and S-HAQ GI subscale (r = 0.446), and the social functioning subscale and SF36v2 role-social domain (r = 0.337), and weak-to-moderate correlation between the emotional subscale and SF-36v2 role-emotional (r = 0.295) and mental health (r = 0.298) domains and mental component summary (r = 0.356). Exploratory factor analysis of the seven subscales yielded a two-factor solution explaining 69.63% of the total variance. This study provides evidence for the reliability and validity of the English and Chinese GIT2.0 to be used in Singapore for research and routine practice.
Literature
1.
go back to reference Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A et al (2011 Feb) Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford) 50(2):330–334CrossRef Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A et al (2011 Feb) Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford) 50(2):330–334CrossRef
2.
go back to reference Marie I, Ducrotte P, Denis P, Menard JF, Levesque H (2009 Oct) Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford) 48(10):1314–1319CrossRef Marie I, Ducrotte P, Denis P, Menard JF, Levesque H (2009 Oct) Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford) 48(10):1314–1319CrossRef
3.
go back to reference Dinesh K, Ron DH, Paul M, James RS, Ann I, Maureen DM et al (2009) Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Care & Research 61(9):1257–1263CrossRef Dinesh K, Ron DH, Paul M, James RS, Ann I, Maureen DM et al (2009) Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Care & Research 61(9):1257–1263CrossRef
4.
go back to reference Khanna D, Hays RD, Park GS, Braun-Moscovici Y, Mayes MD, McNearney TA et al (2007 Oct 15) Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 57(7):1280–1286CrossRefPubMed Khanna D, Hays RD, Park GS, Braun-Moscovici Y, Mayes MD, McNearney TA et al (2007 Oct 15) Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 57(7):1280–1286CrossRefPubMed
5.
go back to reference Cheung YB, Thumboo J (2006) Developing health-related quality-of-life instruments for use in Asia: the issues. PharmacoEconomics 24(7):643–650CrossRefPubMed Cheung YB, Thumboo J (2006) Developing health-related quality-of-life instruments for use in Asia: the issues. PharmacoEconomics 24(7):643–650CrossRefPubMed
8.
go back to reference Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980 May) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581–590CrossRef Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980 May) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581–590CrossRef
10.
go back to reference Ng XY, Thumboo J, Low AHL (2012) Validation of the scleroderma health assessment questionnaire and quality of life in English and Chinese-speaking patients with systemic sclerosis. Int J Rheum Dis 15:268–276CrossRefPubMed Ng XY, Thumboo J, Low AHL (2012) Validation of the scleroderma health assessment questionnaire and quality of life in English and Chinese-speaking patients with systemic sclerosis. Int J Rheum Dis 15:268–276CrossRefPubMed
11.
go back to reference Thumboo J, Wu Y, Tai ES, Gandek B, Lee J, Ma S et al (2013 Nov) Reliability and validity of the English (Singapore) and Chinese (Singapore) versions of the Short-Form 36 version 2 in a multi-ethnic urban Asian population in Singapore. Qual Life Res 22(9):2501–2508CrossRefPubMed Thumboo J, Wu Y, Tai ES, Gandek B, Lee J, Ma S et al (2013 Nov) Reliability and validity of the English (Singapore) and Chinese (Singapore) versions of the Short-Form 36 version 2 in a multi-ethnic urban Asian population in Singapore. Qual Life Res 22(9):2501–2508CrossRefPubMed
12.
go back to reference Sow WT, Wee HL, Wu Y, Tai ES, Gandek B, Lee J et al (2014 Jan) Normative data for the Singapore English and Chinese SF-36 version 2 health survey. Ann Acad Med Singap 43(1):15–23PubMed Sow WT, Wee HL, Wu Y, Tai ES, Gandek B, Lee J et al (2014 Jan) Normative data for the Singapore English and Chinese SF-36 version 2 health survey. Ann Acad Med Singap 43(1):15–23PubMed
13.
go back to reference Beaton DE, Bombardier C, Guillemin F, Ferraz MB (2000 Dec 15) Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 25(24):3186–3191CrossRefPubMed Beaton DE, Bombardier C, Guillemin F, Ferraz MB (2000 Dec 15) Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 25(24):3186–3191CrossRefPubMed
14.
go back to reference Bae S, Allanore Y, Coustet B, Maranian P, Khanna D (2011 Mar-Apr) Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Clin Exp Rheumatol 29(2 Suppl 65):S15–S21PubMed Bae S, Allanore Y, Coustet B, Maranian P, Khanna D (2011 Mar-Apr) Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Clin Exp Rheumatol 29(2 Suppl 65):S15–S21PubMed
15.
go back to reference Meijs J, Pors D, Vliet Vlieland TP, Huizinga TW, Schouffoer AA (2014) Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch. Clin Exp Rheumatol 32:S41–S48 Meijs J, Pors D, Vliet Vlieland TP, Huizinga TW, Schouffoer AA (2014) Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch. Clin Exp Rheumatol 32:S41–S48
16.
go back to reference Gualtierotti R, Ingegnoli F, Two R, Meroni PL, Khanna D, Adorni G et al (2015 Jul-Aug) Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. Clin Exp Rheumatol 33(4 Suppl 91):S55–S60PubMed Gualtierotti R, Ingegnoli F, Two R, Meroni PL, Khanna D, Adorni G et al (2015 Jul-Aug) Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. Clin Exp Rheumatol 33(4 Suppl 91):S55–S60PubMed
17.
go back to reference Baron M, Hudson M, Steele R, Lo E (2011 Sep) Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. J Rheumatol 38(9):1925–1930CrossRefPubMed Baron M, Hudson M, Steele R, Lo E (2011 Sep) Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. J Rheumatol 38(9):1925–1930CrossRefPubMed
18.
go back to reference Santosa A, Tan CS, Teng GG, Fong W, Lim A, Law WG et al (2016) Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort. Scand J Rheumatol 45(6):499–506CrossRefPubMed Santosa A, Tan CS, Teng GG, Fong W, Lim A, Law WG et al (2016) Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort. Scand J Rheumatol 45(6):499–506CrossRefPubMed
19.
go back to reference Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G et al (2015 Apr) Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 74(4):730–737CrossRefPubMed Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G et al (2015 Apr) Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 74(4):730–737CrossRefPubMed
20.
go back to reference Thumboo J, Fong KY, Machin D, Chan SP, Leon KH, Feng PH et al (2001) A community-based study of scaling assumptions and construct validity of the English (UK) and Chinese (HK) SF-36 in Singapore. Qual Life Res 10(2):175–188CrossRefPubMed Thumboo J, Fong KY, Machin D, Chan SP, Leon KH, Feng PH et al (2001) A community-based study of scaling assumptions and construct validity of the English (UK) and Chinese (HK) SF-36 in Singapore. Qual Life Res 10(2):175–188CrossRefPubMed
21.
go back to reference Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B (1998 Nov) Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51(11):1045–1053CrossRefPubMed Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B (1998 Nov) Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51(11):1045–1053CrossRefPubMed
22.
go back to reference Perkins JJ, Sanson-Fisher RW (1998 Nov) An examination of self- and telephone-administered modes of administration for the Australian SF-36. J Clin Epidemiol 51(11):969–973CrossRefPubMed Perkins JJ, Sanson-Fisher RW (1998 Nov) An examination of self- and telephone-administered modes of administration for the Australian SF-36. J Clin Epidemiol 51(11):969–973CrossRefPubMed
Metadata
Title
Validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 in English- and Chinese-speaking patients in a multi-ethnic Singapore systemic sclerosis cohort
Authors
Andrea Hsiu Ling Low
Xiaohui Xin
Weng Giap Law
Gim Gee Teng
Amelia Santosa
Anita Lim
Grace Chan
Swee Cheng Ng
Julian Thumboo
Publication date
01-07-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 7/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3529-x

Other articles of this Issue 7/2017

Clinical Rheumatology 7/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.